Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

While Wall Street analysts remain cautious on Hims & Hers Health ($HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way ...

Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs.

Doon University-BCYW Foundation's Event Speakers Addressing the Audience. Audience Keenly Waiting to Learn from the Speakers. Speake ...

Shedeur Sanders' NFL debut had plenty of anticipation, but it wasn't just his throws that caught fans' attention. The Cleveland Browns rookie quarterback found himself in a moment ...

Detailed price information for Gsi Technology Inc (GSIT-Q) from The Globe and Mail including charting and trades.

In a Georgia courtroom that could’ve easily been heavy with nothing but pain and anger, widow Regina Johnson shocked ...